ag真人平台官方
Other Affiliated Sites
Simplified Chinese
Traditional Chinese
ag真人平台官方:About Hepalink
ag真人平台官方:Group Profile
Corporate Philosophy
ag真人平台官方:Milestones
ag真人平台官方:Leadership Team
ag真人平台官方:Scientific Advisory Board
ag真人平台官方:Our Businesses
Heparin Business
ag真人平台官方:Global Industrial Chain
Global Heparin Injections Business
Product Profile
ag真人平台官方:CDMO Services
ag真人平台官方:Innovative Drugs
ag真人平台官方:Global Manufacturing
ag真人平台官方:Company News
ag真人平台官方:Investor Relations
ag真人平台官方:Corporate Governance
ag真人平台官方:Disclosures
ag真人平台官方:Stock Information
ag真人平台官方:IR Events
ag真人平台官方:IR Contact
Join Us
Career Development
ag真人平台官方:Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
ag真人平台官方:A-Share Information
H-Share Information
A-Share Information
ag真人平台官方:H-Share Information
2020.10.30
2020年第三季度报告全文
2020.10.27
关于依诺肝素钠注射液率先通过仿制药一致性评价的公告
2020.10.27
2019年面向合格投资者公开发行公司债券(第一期)2020年度付息公告
2020.10.27
关于依诺肝素钠注射液率先通过仿制药一致性评价的公告
第一页
上一页
26
27
28
29
30
下一页
最后一页
About Hepalink
ag真人平台官方:Group Profile
ag真人平台官方:Corporate Philosophy
Milestones
ag真人平台官方:Leadership Team
ag真人平台官方:Scientific Advisory Board
Our Businesses
ag真人平台官方:Heparin Business
ag真人平台官方:CDMO Services
ag真人平台官方:Innovative Drugs
ag真人平台官方:Global Manufacturing
ag真人平台官方:Company News
Investor Relations
ag真人平台官方:Corporate Governance
Disclosures
ag真人平台官方:Stock Information
ag真人平台官方:IR Events
ag真人平台官方:IR Contact
Join Us
Career Development
Contact Us
Official WeChat Account
ag真人平台官方:Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.